ReviewNature reviews. Cardiology2026
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.
Review in Nature reviews. Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Drug-Intervention Lag Phase Between Low-Density Lipoprotein-Cholesterol Lowering and Coronary Plaque Stabilization.Circulation reports · 2026Article
- Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies.Journal of clinical medicine · 2026Review
- Subclinical Atherosclerosis, Hyperlipidemia and New-Onset Diabetes Should Not Be Ignored Despite Initial Angiographic Exclusion of Significant Atherosclerotic Occlusive Arterial Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Dynamic Complement Activation Predicts 12-Month Major Adverse Cardiovascular Events in Acute Coronary Syndromes.Biomedicines · 2026Article
- Targeted proteomics of extreme vascular phenotypes in type 1 diabetes: the ESCAPER study.Cardiovascular diabetology · 2026Article
- Precision cardiovascular-kidney-metabolic care - ready for prime time? A fellow's voice.American journal of preventive cardiology · 2026Article
- Winter Temperature and Long-Term Mortality After Coronary Artery Bypass Grafting: A Multicenter Cohort Study.Journal of clinical medicine · 2026Article
- State-Dependent DNA Methylation Signatures Distinguish Acute from Stable Coronary Syndromes.International journal of molecular sciences · 2026Article
- VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Integrating Network Pharmacology and In Vitro Experiments to Elucidate the Antiatherosclerotic Mechanisms of Qingxin Tongmai Yin.Mediators of inflammation · 2026Article
- Latent Profiles and Associated Factors of Health Problem-Solving Ability in Patients with Coronary Heart Disease: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Association between neutrophil extracellular traps, the Von Willebrand factor axis, and clinical outcome in stable coronary artery disease.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite substantial advances in the secondary prevention of cardiovascular disease, atherosclerosis of the coronary arteries and its consequences remain the leading cause of death worldwide. Residual cardiovascular risk refers to the ongoing risk of recurrent cardiovascular events that persists in patients with coronary artery disease despite receiving optimal secondary prevention treatment and effective control of conventional risk factors. Lifestyle modification and therapies modulating thrombosis, blood pressure and LDL-cholesterol levels represent the standard approach for the prevention of recurrent cardiovascular events in patients with coronary artery disease. However, current evidence-based therapies and lifestyle modification strategies only partially modulate the pathophysiological pathways involved in the progression and destabilization of atherosclerotic disease, and other mechanisms might have an important role, accounting, at least in part, for the residual cardiovascular risk in these patients. In this Review, we appraise the available evidence and latest insights into the mechanisms and associated biomarkers of recurrent adverse cardiovascular events and provide perspectives on strategies to reduce residual cardiovascular risk in patients with coronary artery disease.
Indexed as
Identifiers
41577834What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.